AMGN vs MRNA
Amgen Inc. and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | AMGN | MRNA |
|---|---|---|
| Revenue | $36.8B | $1.9B |
| Net income | $7.7B | $-2.8B |
| Gross margin | 67.2% | 55.3% |
| Net margin | 21.0% | −145.2% |
| Return on equity | 106.1% | −28.9% |
| Diluted EPS | $14.23 | −$7.26 |
| Dividend / share | $9.66 | — |
| Payout ratio | 66.5% | — |
| Free cash flow | $8.1B | $-2.1B |
| Equity | $8.7B | $8.7B |
| Net debt / equity | 5.25× | −0.23× |
| Current ratio | 1.14× | 3.29× |
| Revenue CAGR 5y | 7.6% | 19.3% |
| Profit CAGR 5y | 1.2% | — |
AMGN bills 18.9× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | AMGN | MRNA |
|---|---|---|
| FY2025 | $36.8B | $1.9B |
| FY2024 | $33.4B | $3.2B |
| FY2023 | $28.2B | $6.8B |
| FY2022 | $26.3B | $19.3B |
| FY2021 | $26.0B | $18.5B |
| FY2020 | $25.4B | $803.0M |
| FY2019 | $23.4B | $60.0M |
| FY2018 | $23.7B | $135.1M |
| FY2017 | $22.8B | $205.8M |
| FY2016 | $23.0B | $108.4M |
Net income by year
Bottom line
| Fiscal year | AMGN | MRNA |
|---|---|---|
| FY2025 | $7.7B | $-2.8B |
| FY2024 | $4.1B | $-3.6B |
| FY2023 | $6.7B | $-4.7B |
| FY2022 | $6.6B | $8.4B |
| FY2021 | $5.9B | $12.2B |
| FY2020 | $7.3B | $-747.0M |
| FY2019 | $7.8B | $-514.0M |
| FY2018 | $8.4B | $-384.7M |
| FY2017 | $2.0B | $-255.9M |
| FY2016 | $7.7B | $-216.2M |
Advertisement
AdSense · Rectangle 336×280
More in this industry